Used primarily as an active metabolite in the body following administration of mifepristone, it contributes significantly to the overall pharmacological effect of the parent drug. It acts as a potent antagonist of the glucocorticoid and progesterone receptors, making it relevant in the termination of early pregnancy when combined with a prostaglandin. Its activity also supports use in medical regimens for managing conditions like Cushing's syndrome, where control of hypercortisolism is required. Due to its receptor-blocking properties, it has been studied in psychiatric and oncological research, particularly in depression and certain hormone-sensitive tumors. Its presence prolongs the therapeutic effect of mifepristone, enhancing both efficacy and duration of action.